Back

Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry

26 August 2023 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and stable coronary artery disease Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Viveca Ritsinger

Karolinska Institute, Stockholm (Sweden)

6 More presentations in this session

Presentation thumbnail
Does prediabetes diagnosed by hemoglobinA1c or oral glucose tolerance test predict coronary artery disease in patients suspected of chronic coronary syndrome?
Doctor K. Overgaard (Svendborg, DK)
Abstract Slides Video
Presentation thumbnail
Vessel-oriented cardiovascular events in patients with diabetes undergoing intracoronary physiology-guided revascularization
Doctor S. Sgreva (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Synergistic adverse impact of diabetes and chronic kidney disease on cardiovascular mortality in patients underwent percutaneous coronary intervention
Doctor S. Moriya (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Diabetes mellitus and response to IL-1 blockade with Anakinra after ST-elevation myocardial infarction: a pooled analysis of the VCU-ART studies
Doctor A. Abbate (Charlottesville, US) Doctor F. Moroni (Charlottesville, US)
Abstract Slides Video
Presentation thumbnail
Impact of diabetes status and chronic kidney disease on myocardial infarction mortality among elderly patients - a retrospective analysis of data from an ongoing nationwide registry.
Doctor P. Asser (Tartu, EE)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and stable coronary artery disease

The Event

Event poster

ESC Congress 2023

26 August 2023 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study
thumbnail
Congress Presentation
GLP-1 receptor agonists and SGLT2-inhibitors in patients with diabetes and ischaemic heart disease in primary care
thumbnail
Congress Presentation
Low utilization of GLP-1RAs and SGLT2i in high-risk cardiovascular patients with diabetes: nationwide insights from myocardial Infarction and stroke survivors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources